December 19, 2017 / 2:18 PM / a month ago

BRIEF-Asklepion Pharmaceuticals Announces SPA Agreement With FDA For Phase 3 Intravenous Citrulline Program

Dec 19 (Reuters) -

* ASKLEPION PHARMACEUTICALS ANNOUNCES SPECIAL PROTOCOL ASSESSMENT (SPA) AGREEMENT WITH FDA FOR PHASE 3 PROGRAM OF INTRAVENOUS CITRULLINE Source text for Eikon:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below